Stopping the message before
it becomes a disease programme.
Scroll to walk the pathway — from β-catenin behaving normally at the membrane to the proposed biological consequence of lesion regression. The cell membrane stays structurally intact throughout.
Regulated at the membrane.
In healthy behaviour, β-catenin contributes to cell–cell adhesion through cadherin-associated complexes. This is a legitimate, essential structural role — and NBetaX is designed to leave it untouched.
Cytoplasmic accumulation.
Disease-associated signalling increases the availability or activity of β-catenin. It escapes normal regulation and accumulates in the cytoplasm, becoming available for nuclear transport.
Movement toward the nucleus.
β-catenin travels toward the nuclear pores and enters the nucleus, where it can participate in transcriptional complexes.
The message becomes a programme.
Inside the nucleus, genes associated with persistence, invasion, inflammatory signalling, tissue remodelling and fibrosis may become activated — the biology that lets a lesion survive, invade and return.
Selective interception.
N-BX01 is being engineered to interfere selectively with a molecular step required for pathological nuclear β-catenin activity — synthesized by Bogdan Dicoias on the SYNTHESERACT™ CF-SPPS machine. Useful β-catenin biology is preserved; pathological nuclear activity is excluded.
The programme goes quiet.
With the pathological nuclear route intercepted, disease-associated transcription fades. The lesion begins to lose the molecular advantage that sustains it.
The lesion contracts.
Reduced lesion fitness could diminish invasive behaviour and permit regression, while immune-clearance cells enter the resolving tissue.
Proposed biological consequence — not a guaranteed resultThe literature behind the walkthrough.
Each step above rests on published Wnt/β-catenin science. The therapeutic hypothesis for endometriosis was stated in 2014 and reviewed in 2026; the closest preclinical precedent is an animal study, and the peptide modality is published in chemical-biology and oncology contexts. Animal and in vitro results are not evidence of effect in humans.
- Targeting the Wnt/β-catenin pathway in endometriosis: a potentially effective approach for treatment and prevention — Matsuzaki S et al., Molecular and Cellular Therapies, 2014 (review)
- Targeting the Wnt signaling network in endometriosis: mechanistic insights and translational opportunities† — Ye X et al., Biology of Reproduction, 2026 (review)
- β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis — Hirakawa T et al., Scientific Reports, 2019 (in vitro and animal)
- Cell Permeable Stapled Peptide Inhibitor of Wnt Signaling that Targets β-Catenin Protein-Protein Interactions — Dietrich L et al., Cell Chemical Biology, 2017 (chemical biology)
- Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors — Sang P et al., PNAS, 2019 (oncology context)
- Inhibition of Wnt Signaling Using Axin Peptidomimetics through Direct Targeting of β-Catenin — Sang P et al., Journal of Medicinal Chemistry, 2026 (chemical biology)